DCT Advisors Approve $22 Mil. Set Aside For Interactive R01s Systemic Therapies
In Brief: NCI Awards 4 Contracts For Enrichment Program; Dana-Farber Names Breast Center Leadership
NIH Authorization Set For Another Try; Women’s Cancers Are Targeted
DCT Advisers Ok Expansion of Phase 1, Phase 2 Testing
More DCT Concepts Approved By Advisors
Taxotere Encouraging, CPT-11, Other Agents Entering Trials; Chabner
Procedures For Ending IGs Announced
Trending Stories
- Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology - Imaging’s ride to the bottom in clinical trials—and why it matters now
- NIH says it’s moving away from animal-based models
- In the Headlines: Is oncology ready to move away from animal testing?
- The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentum
As oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic - ODAC nixes GSK’s Blenrep myeloma regimens, citing ocular toxicity, dosing, applicability to U.S. population